The same peptide family behind the big human weight-loss drugs is now being tested in cats. Here's where that research actually stands. 🐱 DIABETIC CATS In a placebo-controlled trial, 30 newly diabetic cats got exenatide (a GLP-1 peptide) or saline on top of insulin and a low-carb diet. It looked safe and the cats didn't gain weight, but the remission difference wasn't statistically significant. Less appetite and vomiting were common (J Vet Intern Med 2016, PubMed 26700409). A two-year follow-up in 22 cats already in remission found no difference in how long remission lasted versus placebo (J Vet Intern Med 2025, PMC11921135). ⚖️ OVERWEIGHT CATS Early trials are testing GLP-1 for feline weight loss, including a six-month implant study called MEOW-1 run under an FDA investigational animal drug file. Nothing is approved yet, and there's no GLP-1 weight-loss drug for cats on the market. 🐄 FARM ANIMALS Researchers are also looking at antimicrobial peptides as a possible backup to antibiotics in pigs, poultry and dairy cows. Most of it is still lab and early field work (Frontiers in Veterinary Science 2022). Education only, not veterinary advice. Your vet is the right call for your animal. Takeaway: vet peptide research is real and moving, but "being studied" isn't the same as "approved." Premium goes deeper with full protocols, 20+ graded vendors and weekly $/mg. It's $9/mo and the first 7 days are free 👉 https://www.skool.com/peptideindex/about

Cagrilintide keeps showing up next to semaglutide in weight-loss news. Here's what it actually is. WHAT IT IS • A long-acting, lab-made version of amylin, a hormone your pancreas releases alongside insulin after you eat • Built to last much longer in the body than natural amylin or the older amylin drug pramlintide • Developed by Novo Nordisk, the company behind semaglutide HOW IT WORKS • Amylin is a fullness signal: it slows how fast the stomach empties and tells the brain you've eaten • Cagrilintide hits amylin receptors and related calcitonin receptors • It works on a different pathway than GLP-1 drugs, which is why researchers pair the two WHAT THE RESEARCH LOOKS AT • Phase 2 trial in adults with obesity (Lancet 2021): up to about 11% average weight loss over 26 weeks vs about 3% on placebo • CagriSema, cagrilintide plus semaglutide, in the phase 3 REDEFINE 1 trial (NEJM 2025): about 20% average weight loss over 68 weeks vs about 3% on placebo • The most common side effects were stomach-related, like nausea and constipation Evidence level: Moderate to strong in human trials, mostly as part of CagriSema. Exact dosing and timing are in the Premium classroom. For research use only, not medical advice. Takeaway: cagrilintide is the amylin half of CagriSema, a second fullness signal that researchers are stacking on top of GLP-1s.